KKR Closes $2.1 Billion Leveraged Loan for Integer Holdings Acquisition at Favorable Terms

The Quick Take

• KKR finalized a $2.1 billion leveraged loan to fund its acquisition of Integer Holdings, the medical device manufacturer, after securing more favorable terms than initially offered — a sign of strong institutional appetite for high-quality PE credit even in the elevated-rate environment
• Bloomberg reports that the loan terms improved during syndication, with KKR 'seizing on investor demand' — suggesting that the private equity firm was able to negotiate tighter spreads as institutional lenders competed to participate in the deal
• The successful $2.1 billion leveraged financing in a period of Fed rate hike certainty and elevated Treasury yields demonstrates that the leveraged loan market remains open for investment-grade private equity transactions, though at higher all-in costs than the 2020-2022 era

KKR & Co. completed the $2.1 billion leveraged loan financing for its acquisition of Integer Holdings, a medical device manufacturer, according to Bloomberg Markets reporting. The noteworthy element of the deal's execution is not merely the size — $2.1 billion is a substantial leveraged loan — but the pricing dynamics: KKR secured 'more favorable terms' than the deal was initially marketed at, suggesting that institutional demand from banks, insurance companies, and CLO (collateralized loan obligation) vehicles exceeded initial syndication expectations. Bloomberg describes KKR as 'seizing on investor demand' to improve pricing, which in leveraged loan parlance means the spread above SOFR (the floating rate benchmark) was tightened as oversubscription gave KKR negotiating leverage.

The market significance of KKR closing $2.1 billion in leveraged financing at favorable terms in September 2026 lies in what it reveals about the leveraged loan market's health in a high-rate environment. With the Federal Reserve's September rate hike bringing the policy rate to elevated levels, corporate borrowers have faced rising debt service costs and more stringent lending conditions throughout the tightening cycle. However, the market for high-quality private equity-sponsored credits — deals backed by KKR-caliber sponsors with strong portfolio company management and demonstrated exit capabilities — has remained relatively open, with investors seeking the yield premium that leveraged loans provide over investment-grade corporate bonds or government securities. The favorable terms KKR achieved signal that the leveraged loan market is differentiating between sponsor quality rather than blanket repricing all PE-backed debt.

Integer Holdings, the target company in KKR's acquisition, is a medical device contract manufacturer serving cardiac rhythm management, neurostimulation, and vascular therapy device makers. The healthcare device sector's non-cyclical demand characteristics — medical devices are not discretionary spending — provide the cash flow predictability that supports $2.1 billion in debt service, even in a higher-for-longer rate scenario. KKR's ability to secure favorable terms on Integer's financing confirms the thesis that defensive healthcare assets with predictable revenue streams command a premium in the leveraged loan market relative to cyclical or consumer-facing LBO targets. The transaction is expected to close subject to regulatory review, after which Integer's operating performance under KKR's ownership will determine whether the acquisition thesis justifies the leverage multiple implied by the $2.1 billion loan.

Synthesized from 1 source.